Cancer Prevention Research · 2015 · 24 citations · 28 references
Life SciencesImmunologyOncologyAutoimmunityCancer ImmunologyEarly DetectionAutoantibodiesAutoimmune BiomarkersCancer BiomarkersCancer Early DetectionTumor AntigensTumor-associated AntigensAutoantibody AssaysAutoantibody BiomarkersAutoantibody ProfilingAutoantibody SignaturesDiagnostic Testing AccuracyImmunoassay BiomarkersImmunodiagnostic BiomarkersReceiver Operating Characteristic Analysis
Nasopharyngeal carcinoma (NPC) is prevalent in Southern China and Southeast Asia, and autoantibody signatures may improve early detection of NPC. In this study, serum levels of autoantibodies against a panel of six tumor-associated antigens (p53, NY-ESO-1, MMP-7, Hsp70, Prx VI, and Bmi-1) and Epstein-Barr virus capsid antigen-IgA (VCA-IgA) were tested by enzyme-linked immunosorbent assay in a training set (220 NPC patients and 150 controls) and validated in a validation set (90 NPC patients and 68 controls). We used receiver-operating characteristics (ROC) to calculate diagnostic accuracy. ROC curves showed that use of these 6 autoantibody assays provided an area under curve (AUC) of 0.855 [95% confidence interval (CI), 0.818-0.892], 68.2% sensitivity, and 90.0% specificity in the training set and an AUC of 0.873 (95% CI, 0.821-0.925), 62.2% sensitivity, and 91.2% specificity in the validation set. Moreover, the autoantibody panel maintained diagnostic accuracy for VCA-IgA-negative NPC patients [0.854 (0.809-0.899), 67.8%, and 90.0% in the training set; 0.879 (0.815-0.942), 67.4%, and 91.2% in the validation set]. Importantly, combination of the autoantibody panel and VCA-IgA improved diagnostic accuracy for NPC versus controls compared with the autoantibody panel alone [0.911 (0.881-0.940), 81.4%, and 90.0% in the training set; 0.919 (0.878-0.959), 78.9%, and 91.2% in the validation set), as well as for early-stage NPC (0.944 (0.894-0.994), 87.9%, and 94.0% in the training set; 0.922 (0.808-1.000), 80.0%, and 92.6% in the validation set]. These results reveal autoantibody signatures in an optimized panel that could improve the identification of VCA-IgA-negative NPC patients, may aid screening and diagnosis of NPC, especially when combined with VCA-IgA.
28
Serum protein markers for early detection of ovarian cancer
Gil Mor, Irene Visintin, Yinglei Lai et al. · Proceedings of the National Academy of Sciences · 2005 · 523 citations · Full text
Medicine, Gynecology, Oncology +16
Fingerprinting the circulating repertoire of antibodies from cancer patients
Paul J. Mintz, Jeri Kim, Kim‐Anh Do et al. · Nature Biotechnology · 2002 · 357 citations
Life Sciences, Immunology, Oncology +12
Autoantibodies in lung cancer: possibilities for early detection and subsequent cure
Caroline Chapman, Alan Murray, J. McElveen et al. · Thorax · 2007 · 337 citations · Full text
Life Sciences, Immunology, Oncology +17